0.00
—
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Biotron
Its shares trade on ASX under the ticker BIT.AX. It has been listed since 24 January 2001. In the fiscal year to 30 June 2025, it reported revenue of A$1.8m and a net loss of A$318,572. At that date it held total assets of A$980,401 and shareholders' equity of A$551,895.
Biotron Ltd. is a clinical stage Australian biotechnology company. The company is headquartered in North Ryde, New South Wales. The company went IPO on 2001-01-24. The firm is engaged in the funding and management of intermediate, and applied biotechnology research and development projects. The firm is focused on the ongoing clinical development of its antiviral platform. The firm's lead antiviral drug, BIT225 is in mid-stage clinical development with approximately eight clinical trials completed. The firm has conducted clinical trails in human immunodeficiency virus-1 (HIV-1), hepatitis C virus (HCV) and HIV-1/HCV co-infected population. The clinical trials showed that BIT225 targets and reduces levels of HIV-1 residing in long-lived monocyte/macrophage reservoirs. BIT225 has clinical antiviral activity against both HIV-1 and HCV. BIT225 is pan-genotypic and is active against all HCV genotypes, including GT3. The firm designs and develops drugs that target a class of virus protein known as viroporins. Its earlier stage programs include Dengue, Influenza and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 24 Jan 2001
- Employees
- 4
- Website
- biotron.com.au ↗
Leadership
Pay as last reported
- Mr. Michael HoyIndependent Non-Executive Chairman of the BoardA$82,500
- Dr. Michelle MillerManaging Director, Executive Director, since 2002A$380,439
- Mr. Peter NightingaleCompany SecretaryA$84,000
- Mr. Robert ThomasIndependent Non-Executive DirectorA$44,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Biotron Ltd possesses several key strengths that contribute to its success in the market. These strengths include:
- Despite its strengths, Biotron Ltd also faces certain weaknesses that can hinder its performance and growth prospects. These weaknesses include:
- Biotron Ltd can leverage certain opportunities in the market to drive its growth and expansion. These opportunities include:
- Biotron Ltd faces certain threats that may pose challenges to its operations and future growth. These threats include:
Weaknesses
- Despite its strengths, Biotron Ltd also faces certain weaknesses that can hinder its performance and growth prospects. These weaknesses include:
- Biotron Ltd can leverage certain opportunities in the market to drive its growth and expansion. These opportunities include:
- Biotron Ltd faces certain threats that may pose challenges to its operations and future growth. These threats include:
Opportunities
- Biotron Ltd can leverage certain opportunities in the market to drive its growth and expansion. These opportunities include:
- Biotron Ltd faces certain threats that may pose challenges to its operations and future growth. These threats include:
Threats
- Biotron Ltd faces certain threats that may pose challenges to its operations and future growth. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.